European Archives - Page 2 of 1233 - European Medical Journal

Which National Strategies Best Curb Drug-Resistant Infections?

Global disparities in AMR governance show high-income countries with stronger plans, while low-income nations face weaker strategies and higher infection burdens.

Excisional Biopsy Alone May Suffice in Melanoma Treatment

Importantly, patients with clear margins from excisional biopsy alone, who did not undergo wide excision, showed no recurrence after a median of more than eight years.

Air Pollution Drives Toxic Protein Linked to Lewy Body Dementia

Air pollution may drive Lewy body dementia by triggering toxic brain protein clumps, new research shows.

Antibiotic Prophylaxis and Distal Ileum Microbiota in Cystectomy

This study investigated the microbiota of the distal ileum in patients undergoing iRARC without bowel preparation, using direct sampling during ICUD.

Lower Steroid Use Drives Pregnancy Asthma Hospitalisations

Hospital asthma exacerbations rise in later pregnancy, with reduced inhaled corticosteroid use a key modifiable risk factor, UK data show.

Over 100 Nations Join Global AI Model to Redefine Bias and Diversity in AI

Global RETFound model unites 100 countries to build more equitable, diverse AI for medical research and patient care.

Bridging the Gap Between AI Research and Immunology

Discover a study exploring how AI can transform allergy and immunology, highlighting challenges, opportunities, and a roadmap for clinical impact.

Immune Genes Driving MAFLD Progression and Diagnosis Revealed

Emerging evidence points to the role of CD4+ T cell subsets in fuelling MAFLD-related inflammation and fibrosis.

LSD-Based Treatment Achieves Rapid Anxiety Relief in Clinical Trial

Single-dose MM120 provides fast, lasting anxiety relief in generalised anxiety disorder, paving the way for new treatments.

Coins falling

ABPI report highlights decline in UK pharma investment

The latest ABPI and PwC Pharmaceutical Competitiveness Framework reveals the UK is losing ground in pharma R&D, investment, and clinical trials, with rankings slipping sharply since 2018.